Tumor Size Reduction and Serum Carbohydrate Antigen 19-9 Kinetics After Neoadjuvant FOLFIRINOX in Patients With Pancreatic Ductal Adenocarcinoma

Changes in tumor size and serum carbohydrate antigen 19-9 are commonly reported markers used to assess response to neoadjuvant therapy in pancreatic ductal adenocarcinoma. We evaluated the impact of the percentual tumor size reduction and carbohydrate antigen 19-9 kinetics on resectability and response to neoadjuvant FOLFIRINOX.

Source: Surgery - November 8, 2023 Category: Surgery Authors: Maximiliano Servin-Rojas, Zhi Ven Fong, Carlos Fernandez-Del Castillo, Cristina R. Ferrone, Hang Lee, Fidel Lopez-Verdugo, Guoliang Qiao, Dario M. Rocha-Castellanos, Keith D. Lillemoe, Motaz Qadan Source Type: research